Alexandros D Tselepis Selected Research

Thrombosis (Thrombus)

1/2019	The pathway of neutrophil extracellular traps towards atherosclerosis and thrombosis.
1/2019	Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial.
1/2018	Designing Natural Product Hybrids Bearing Triple Antiplatelet Profile and Evaluating Their Human Plasma Stability.
1/2017	Antiplatelet Agents and Anticoagulants: From Pharmacology to Clinical Practice.
1/2012	The platelet hyporesponsiveness to clopidogrel in acute coronary syndrome patients treated with 75 mg/day clopidogrel may be overcome within 1 month of treatment.
1/2011	A highly constrained cyclic (S,S)-CDC- peptide is a potent inhibitor of carotid artery thrombosis in rabbits.
1/2010	The antiplatelet and antithrombotic actions of statins.
5/2009	Effect of a synthetic peptide corresponding to residues 313 to 320 of the alphaIIb subunit of the human platelet integrin alphaIIbbeta3 on carotid artery thrombosis in rabbits.
8/2006	Investigation of the role of adjacent amino acids to the 313-320 sequence of the alphaIIb subunit on platelet activation and fibrinogen binding to alphaIIbbeta3.
7/2005	Lipoprotein(a) as a cardiovascular risk factor.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alexandros D Tselepis Research Topics

Disease

25	Atherosclerosis 01/2021 - 12/2002
25	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 12/2002
17	Inflammation (Inflammations) 01/2021 - 12/2002
16	Acute Coronary Syndrome 01/2020 - 03/2004
16	Dyslipidemias (Dyslipidemia) 05/2015 - 02/2002
12	Thrombosis (Thrombus) 01/2019 - 02/2004
9	Hemorrhage 01/2021 - 02/2006
9	Hypercholesterolemia 03/2015 - 02/2002
7	Coronary Artery Disease (Coronary Atherosclerosis) 01/2019 - 12/2002
6	Ischemic Stroke 01/2022 - 07/2006
5	Diabetes Mellitus 01/2021 - 03/2008
5	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2019 - 03/2005
5	Hyperlipidemias (Hyperlipidemia) 03/2009 - 07/2005
4	Hypertension (High Blood Pressure) 01/2021 - 06/2011
4	Myocardial Infarction 01/2021 - 03/2017
4	Rheumatoid Arthritis 05/2018 - 01/2006
4	Hypertriglyceridemia 01/2016 - 10/2004
4	Chronic Renal Insufficiency 01/2014 - 07/2005
3	Stroke (Strokes) 01/2021 - 07/2006
3	Neoplasms (Cancer) 01/2019 - 02/2012
3	Peripheral Arterial Disease 01/2018 - 10/2007
3	Insulin Resistance 01/2017 - 01/2007
3	Overweight 01/2016 - 01/2012
3	Coronary Disease (Coronary Heart Disease) 03/2015 - 12/2002
3	Prediabetic State (Prediabetes) 01/2015 - 06/2011
3	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 08/2012 - 10/2006
3	Vascular Diseases (Vascular Disease) 05/2008 - 05/2007
3	Essential Hypertension 01/2007 - 06/2004
2	Colorectal Neoplasms (Colorectal Cancer) 03/2022 - 02/2012
2	Type 2 Diabetes Mellitus (MODY) 01/2021 - 10/2012
2	Proteinuria 01/2021 - 01/2004
2	Crohn Disease (Crohn's Disease) 01/2016 - 09/2014
2	Ulcerative Colitis 01/2016 - 09/2014
2	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2016 - 09/2014
2	Necrosis 08/2014 - 10/2009
2	Infections 08/2014 - 10/2011
2	Death (Near-Death Experience) 01/2014 - 11/2012
2	Wounds and Injuries (Trauma) 03/2012 - 02/2012
2	Carotid Artery Thrombosis 01/2011 - 05/2009
2	Carotid Artery Diseases 11/2010 - 10/2006

Drug/Important Bio-Agent (IBA)

27	oxidized low density lipoproteinIBA 01/2021 - 02/2002
21	LipidsIBA 01/2021 - 12/2002
21	1-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)IBA 09/2014 - 12/2002
19	Lipoproteins (Lipoprotein)IBA 01/2016 - 02/2002
15	LDL CholesterolIBA 01/2021 - 02/2002
14	EnzymesIBA 01/2015 - 02/2002
11	Rosuvastatin Calcium (Crestor)FDA Link 05/2015 - 07/2007
10	Clopidogrel (Plavix)FDA Link 01/2021 - 03/2004
10	Triglycerides (Triacylglycerol)IBA 01/2021 - 07/2006
10	Lipoprotein(a)IBA 08/2014 - 04/2003
9	CholesterolIBA 01/2017 - 07/2006
8	HDL LipoproteinsIBA 01/2015 - 05/2005
7	HDL CholesterolIBA 01/2021 - 07/2006
7	LDL Lipoproteins (beta Lipoproteins)IBA 05/2018 - 07/2006
7	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2017 - 10/2007
7	Phospholipids (Phosphatides)FDA LinkGeneric 01/2014 - 12/2002
7	Platelet Activating FactorIBA 05/2005 - 02/2002
6	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2019 - 02/2006
6	AutoantibodiesIBA 05/2018 - 08/2006
6	ApolipoproteinsIBA 01/2017 - 07/2006
6	Ezetimibe (Zetia)FDA Link 01/2017 - 10/2007
6	Simvastatin (Zocor)FDA LinkGeneric 03/2015 - 03/2011
6	Atorvastatin (Lipitor)FDA Link 03/2015 - 02/2002
6	Fenofibrate (CiL)FDA LinkGeneric 04/2012 - 05/2003
5	Fibrinogen (Factor I)FDA Link 01/2021 - 02/2004
5	CytokinesIBA 08/2014 - 12/2002
5	Phospholipases (Phospholipase)IBA 12/2013 - 12/2002
5	1-penicillamyl-Leu(2)- oxytocinIBA 08/2012 - 12/2002
4	Apolipoproteins B (ApoB)IBA 01/2021 - 12/2003
4	C-Reactive ProteinIBA 01/2021 - 12/2011
4	AntibodiesIBA 05/2018 - 10/2006
4	AdipokinesIBA 01/2016 - 01/2008
4	Glucose (Dextrose)FDA LinkGeneric 05/2015 - 05/2007
3	Biomarkers (Surrogate Marker)IBA 01/2021 - 09/2009
3	Peptide Hydrolases (Proteases)FDA Link 11/2019 - 11/2017
3	Purinergic P2Y Receptor AntagonistsIBA 01/2019 - 11/2017
3	Aryldialkylphosphatase (Paraoxonase)IBA 08/2014 - 05/2007
3	Apolipoproteins AIBA 08/2014 - 07/2006
3	IntegrinsIBA 05/2009 - 02/2004
3	We 201IBA 10/2006 - 12/2002
3	Apoprotein(a) (Apolipoprotein (a))IBA 07/2006 - 04/2003
3	Protein Isoforms (Isoforms)IBA 07/2006 - 04/2003
2	Apolipoprotein A-I (Apolipoprotein A1)IBA 01/2021 - 12/2003
2	SaltsIBA 01/2020 - 01/2014
2	AntigensIBA 05/2018 - 08/2006
2	Cyclooxygenase 1IBA 01/2018 - 11/2017
2	AdiponectinIBA 01/2016 - 10/2009
2	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2014 - 02/2012
2	Interleukin-6 (Interleukin 6)IBA 12/2012 - 02/2012
2	LipopolysaccharidesIBA 12/2012 - 12/2010
2	HydrogenIBA 10/2012 - 02/2012
2	Sulfates (Sulfates, Inorganic)IBA 10/2012 - 02/2012
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2012 - 10/2009
2	Peptides (Polypeptides)IBA 01/2011 - 05/2009
2	Hemostatics (Antihemorrhagics)IBA 01/2011 - 05/2009
2	Adenosine Diphosphate (ADP)IBA 01/2011 - 08/2005

Therapy/Procedure

19	Therapeutics 07/2021 - 12/2003
5	Secondary Prevention 01/2019 - 01/2017
2	Fat-Restricted Diet (Diet, Fat Restricted) 01/2017 - 01/2016
2	Colectomy 07/2013 - 02/2012